Boron Neutron Capture Therapy of Malignant Gliomas.

Abstract

Boron neutron capture therapy (BNCT) is a promising modality for biochemically targeted, highly selective radiation treatment of various cancers, including malignant gliomas. Currently available results demonstrate the beneficial effect of such therapy on survival of patients with both recurrent and newly diagnosed glioblastomas. The main drawback of BNCT in cases of previously irradiated neoplasms is high rates of symptomatic pseudoprogression and radiation necrosis. For prevention of these complications, concurrent administration of bevacizumab may be helpful. Further studies are needed to establish the optimal therapeutic protocols and to define the exact role of this management option in multimodality treatment strategies. Recent technological developments of accelerator-based neutron sources may simplify placement of the device for BNCT within clinical facilities and lead to wider application of this technique in cases of various cancers.

• Authors: Shin-Ichi Miyatake, Shinji Kawabata, Ryo Hiramatsu, Toshihiko Kuroiwa, Minoru Suzuki, Koji Ono
• Journal: Progress in neurological surgery (Prog Neurol Surg) Vol. 32 Pg. 48-56 ( 2018) ISSN: 1662-3924 [Electronic] Switzerland
• PMID: 29990973 (Publication Type: Journal Article, Review)
• Copyright: © 2018 S. Karger AG, Basel.

Chemical References

• Antineoplastic Agents, Immunological
• Bevacizumab

Topics

• Antineoplastic Agents, Immunological (therapeutic use)
• Bevacizumab (therapeutic use)
• Boron Neutron Capture Therapy (adverse effects, methods, standards)
• Brain Neoplasms (drug therapy, radiotherapy)
• Combined Modality Therapy (methods)
• Glioma (drug therapy, radiotherapy)
• Humans
• Radiation Injuries (etiology, prevention & control)